In Alzheimer’s Disease (AD), tau exhibits pathological hyperphosphorylation [1,2], allowing both histological diagnosis by use of tau antibodies against disease specific phosphorylation sites [3,4] and, to a certain extent, even in vivo diagnosis by determination of the protein’s phosphorylation status in cerebrospinal fluid [5,6]. This evidence concerns the gene MAPT and Alzheimer disease.